CG Oncology (CGON) vs Scholar Rock (SRRK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CG Oncology (CGON) has outperformed Scholar Rock (SRRK) over the past year, gaining 64.2% versus a gain of 6.8%. CG Oncology is the larger company by market cap ($5.61 billion vs $5.18 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGON | SRRK |
|---|---|---|
| Share price | $63.34 | $42.55 |
| Market cap | $5.61B | $5.18B |
| 1-day change | +1.54% | +0.83% |
| YTD return | +50.24% | -4.20% |
| 1-year return | +64.16% | +6.84% |
| 5-year return | — | +54.75% |
| EPS (TTM) | $-2.69 | $-3.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.04M | $0 |
| Revenue growth (YoY) | +254.70% | — |
| Net income (latest FY) | $-161.00M | $-377.94M |
| Operating margin | -4722.13% | — |
| Net margin | -3985.02% | — |
| 52-week high | $80.97 | $61.76 |
| 52-week low | $35.80 | $27.07 |
| Distance from 52-week high | -21.77% | -31.10% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +43.80% | +65.55% |
| Average volume | 887.57K | 1.49M |
| Shares outstanding | 88.64M | 121.79M |
| Employees | 142 | 289 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGON has outperformed SRRK by 57.3 percentage points over the past year.
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
About Scholar Rock
SRRK stock →Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 289 employees
CGON vs SRRK FAQ
Which is bigger, CG Oncology or Scholar Rock?
CG Oncology (CGON) is larger, with a market capitalization of $5.61B compared with $5.18B for Scholar Rock (SRRK).
Which stock has performed better over the past year, CGON or SRRK?
CGON returned +64.16% over the past 12 months, compared with +6.84% for SRRK (price return, excluding dividends). Past performance does not predict future results.
Are CG Oncology and Scholar Rock in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.